While Congress has a two-week recess in April, there are many priority items on the agenda this month. Less than two weeks after signing the Fiscal Year (FY) 2022 spending package, President Biden released his budget for FY...more
4/4/2022
/ America Competes Act ,
BsUFA ,
Budgets ,
Centers for Disease Control and Prevention (CDC) ,
Department of Energy (DOE) ,
Energy Sector ,
Food and Drug Administration (FDA) ,
GDUFA ,
Government Shutdown ,
Investment Tax Credits ,
Medical Device User Fee Program (MDUFA IV) ,
Mental Health ,
National Institute of Health (NIH) ,
NATO ,
Nominations ,
Oil & Gas ,
PDUFA ,
Public Health Emergency ,
Russia ,
SAMHSA ,
Semiconductors ,
SFC ,
Ukraine
Despite February being a short month, various proposals are still on the table. As Congress returns from recess this week, it faces a daunting to-do list. Government funding runs out by mid-February, Democrats are looking for...more
...Alexander: Senate Sends Opioids Legislation Called “Landmark” by Leader McConnell to President – On Wednesday, the U.S. Senate passed by a vote of 98-1, the SUPPORT for Patients and Communities Act, sponsored by Senator...more
10/11/2018
/ Centers for Medicare & Medicaid Services (CMS) ,
Department of Health and Human Services (HHS) ,
Electronic Medical Records ,
Food and Drug Administration (FDA) ,
Health Care Providers ,
Legislative Agendas ,
Medicaid ,
Medicare ,
Opioid ,
Pharmaceutical Industry ,
Prescription Drugs ,
Trump Administration
Foley’s Bipartisan Public Policy Team is pleased to share our Public Policy August Recess Health Care Newsletter in which we compiled the top health care policy news and legislation from this month. The House was not in...more
8/28/2018
/ Affordable Care Act ,
Centers for Medicare & Medicaid Services (CMS) ,
Department of Health and Human Services (HHS) ,
Employee Retirement Income Security Act (ERISA) ,
Food and Drug Administration (FDA) ,
Health Care Providers ,
Healthcare ,
HELP ,
Legislative Agendas ,
Medicaid ,
Medicare ,
Prescription Drugs
Foley & Lardner LLP’s Bipartisan Public Policy Team is pleased to share this week’s “Public Policy Health Care Newsletter” in which we compile the latest health care policy news and legislation. Please note that the next...more
7/30/2018
/ Affordable Care Act ,
Centers for Medicare & Medicaid Services (CMS) ,
Department of Health and Human Services (HHS) ,
Drug Pricing ,
Food and Drug Administration (FDA) ,
GAO ,
Health Insurance ,
Healthcare Reform ,
HELP ,
Legislative Agendas ,
Medicare ,
Medicare Part D ,
MIPS ,
National Institute of Health (NIH) ,
Opioid ,
Prescription Drugs ,
Section 340B ,
Trump Administration
Foley & Lardner LLP’s (“Foley”) Bipartisan Public Policy Team is pleased to share our “Public Policy Weekly* Health Care Newsletter” in which we compile the latest Health Care policy news and legislation. *Please note that we...more
7/24/2018
/ Appropriations Bill ,
Biosimilars ,
Centers for Medicare & Medicaid Services (CMS) ,
Department of Health and Human Services (HHS) ,
Drug Pricing ,
Federal Budget ,
Food and Drug Administration (FDA) ,
Healthcare ,
Healthcare Reform ,
Legislative Agendas ,
Legislative Committees ,
Medicaid ,
Medicare ,
Medicare Access and CHIP Reauthorization (MACRA) ,
Opioid ,
Secretary of HHS ,
Stark Law ,
Trump Administration
Foley & Lardner LLP’s (“Foley”) Bipartisan Public Policy Team is pleased to share our “Public Policy Weekly* Health Care Newsletter” in which we compile the latest Health Care policy news and legislation. *Please note that we...more
7/16/2018
/ Affordable Care Act ,
Appropriations Bill ,
Association Health Plans ,
Centers for Medicare & Medicaid Services (CMS) ,
DEA ,
Department of Education ,
Department of Health and Human Services (HHS) ,
Department of Labor (DOL) ,
Electronic Health Record Incentives ,
Employee Retirement Income Security Act (ERISA) ,
Food and Drug Administration (FDA) ,
Funding Opportunities ,
GAO ,
Health Insurance ,
Health Savings Accounts ,
Healthcare Reform ,
HELP ,
Legislative Agendas ,
Medicaid ,
Medicare ,
Medicare Advantage ,
Opioid ,
Pharmaceutical Industry ,
Prescription Drugs ,
Proposed Legislation ,
Proposed Regulation ,
Section 340B ,
Telemedicine
Foley & Lardner LLP’s (“Foley”) Bipartisan Public Policy Team is pleased to share our “Public Policy Weekly* Health Care Newsletter” in which we compile the latest Health care policy news and legislation. *Please note that we...more
7/2/2018
/ Appropriations Bill ,
Centers for Medicare & Medicaid Services (CMS) ,
Department of Health and Human Services (HHS) ,
Drug Pricing ,
FDA Approval ,
Food and Drug Administration (FDA) ,
Healthcare ,
Healthcare Fraud ,
HELP ,
Legislative Agendas ,
Medicaid ,
Medicare ,
New Legislation ,
Opioid ,
Pharmaceutical Industry ,
Proposed Legislation ,
Section 340B ,
Senate Finance Committee ,
Substance Abuse ,
Trump Administration ,
Veterans Administration
Foley & Lardner LLP’s (“Foley”) Bipartisan Public Policy Team is pleased to share our “Public Policy Weekly* Health Care Newsletter” in which we compile the latest Health care policy news and legislation. *Please note that we...more
6/26/2018
/ Affordable Care Act ,
Agency Consolidation ,
Centers for Medicare & Medicaid Services (CMS) ,
Department of Health and Human Services (HHS) ,
Drug Pricing ,
Federal Funding ,
Food and Drug Administration (FDA) ,
Health Care Providers ,
Healthcare Reform ,
HELP ,
Legislative Agendas ,
Medicaid ,
Medicare ,
Opioid ,
Prescription Drugs ,
SAMHSA ,
Stark Law ,
State and Local Government ,
Trump Administration
Foley & Lardner LLP’s (“Foley”) Bipartisan Public Policy Team is pleased to share our “Public Policy Weekly* Health Care Newsletter” in which we compile the latest Health care policy news and legislation. *Please note that we...more
6/21/2018
/ Centers for Medicare & Medicaid Services (CMS) ,
Department of Health and Human Services (HHS) ,
Drug Pricing ,
Food and Drug Administration (FDA) ,
Generic Drugs ,
Healthcare ,
HELP ,
Hospitals ,
Medicaid ,
Medicare ,
National Institute of Health (NIH) ,
Opioid ,
Pharmaceutical Industry ,
Proposed Legislation ,
Secretary of HHS ,
Senate Finance Committee ,
Substance Abuse ,
Trump Administration
Foley’s Bipartisan Public Policy Team is pleased to share our “Public Policy Health Care Newsletter” in which we compile the latest health care policy news and legislation. *Please note that we publish this newsletter only...more
6/12/2018
/ Affordable Care Act ,
Appropriations Bill ,
Centers for Medicare & Medicaid Services (CMS) ,
Cybersecurity ,
Department of Health and Human Services (HHS) ,
Federal Budget ,
Food and Drug Administration (FDA) ,
GAO ,
HELP ,
Legislative Agendas ,
Legislative Committees ,
Medicare ,
Medicare Part D ,
National Institute of Health (NIH) ,
Opioid ,
Pharmaceutical Industry ,
Prescription Drugs ,
Preventive Health Care ,
Substance Abuse ,
Trump Administration ,
Ways and Means Committee
Foley & Lardner LLP’s (“Foley”) Bipartisan Public Policy Team is pleased to share our “Public Policy Weekly Health Care Newsletter” in which we compile the latest health care policy news and legislation....more
5/29/2018
/ Affordable Care Act ,
Centers for Medicare & Medicaid Services (CMS) ,
Children's Health Insurance Program (CHIP) ,
DEA ,
Department of Health and Human Services (HHS) ,
Drug & Alcohol Abuse ,
Food and Drug Administration (FDA) ,
Generic Drugs ,
Health Care Providers ,
Infectious Diseases ,
Legislative Agendas ,
Medicare Part D ,
Opioid ,
Pharmaceutical Industry ,
Prescription Drugs ,
Telemedicine ,
Trump Administration
Foley & Lardner LLP’s (“Foley”) Bipartisan Public Policy Team is pleased to share our “Public Policy Weekly Health Care Newsletter” in which we compile the latest health care policy news and legislation.*Please note that we...more
5/21/2018
/ Affordable Care Act ,
Centers for Medicare & Medicaid Services (CMS) ,
Department of Health and Human Services (HHS) ,
Drug Pricing ,
Federal Funding ,
Food and Drug Administration (FDA) ,
Health Care Providers ,
Healthcare Reform ,
HELP ,
Legislative Agendas ,
Medicaid ,
Medicare ,
Opioid ,
Prescription Drugs ,
Section 340B ,
Trump Administration
Foley & Lardner LLP’s (“Foley”) Bipartisan Public Policy Team is pleased to share our second “Public Policy Weekly* Health Care Newsletter” in which we compile the latest health care policy news and legislation.
Please...more
5/14/2018
/ Affordable Care Act ,
Centers for Medicare & Medicaid Services (CMS) ,
Children's Health Insurance Program (CHIP) ,
DEA ,
Department of Health and Human Services (HHS) ,
Department of Veterans Affairs ,
Drug Pricing ,
Federal Food Drug and Cosmetic Act (FFDCA) ,
Food and Drug Administration (FDA) ,
Health Care Providers ,
Health Insurance ,
Health Insurance Portability and Accountability Act (HIPAA) ,
Healthcare ,
Healthcare Reform ,
Legislative Agendas ,
Medicaid ,
Medicare Part C ,
Mental Health ,
National Institute of Health (NIH) ,
Pharmaceutical Industry ,
Prescription Drugs ,
Regulatory Agenda ,
Section 340B ,
Social Security Act ,
Trade Policy ,
Trump Administration
Foley & Lardner LLP’s (“Foley”) Bipartisan Public Policy Team is pleased to introduce “This Week in Health Care Policy,” a new weekly publication providing a compilation of the latest health care policy news and legislation....more
5/1/2018
/ Centers for Medicare & Medicaid Services (CMS) ,
Department of Health and Human Services (HHS) ,
Department of Veterans Affairs ,
Drug Pricing ,
Food and Drug Administration (FDA) ,
Health Care Providers ,
Information Technology ,
Legislative Agendas ,
Opioid ,
Pharmaceutical Industry ,
Physicians ,
Prescription Drugs ,
Section 340B ,
Telemedicine